TD Cowen analyst Yaron Werber raised the firm’s price target on Ascendis Pharma (ASND) to $162 from $153 and keeps a Buy rating on the shares. The firm said Skytrofa’s $58M Q4 revenues missed conensus as Yorvi was inline with conensus. Skytrofa pricing stabilized so sales should follow volume growth. Yorvi off to a solid launch given pent up demand as most patients many prescribers are new to rPTH.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma price target lowered to $192 from $203 at BofA
- Strong Buy Recommendation for Ascendis Pharma Driven by Yorvipath’s Successful US Launch and Future Growth Potential
- Ascendis Pharma: Promising Developments and Growth Prospects Drive Buy Rating
- Ascendis Pharma A/S Reports Strong 2024 Financial Growth
- Closing Bell Movers: Cisco gains 7%, Robinhood up 15% on earnings